Prospective assessment of risk biomarkers of sinusoidal obstruction syndrome after hematopoietic cell transplantation.

In a randomized trial, its prophylactic administration in a pediatric population resulted in decreased SOS incidence, from 20% to 12%, although the P values were just at the limit of significance ( Z test for competing risk analysis P = 0.0488; log-rank test P = 0.0507) ( 10 , 11 ).

also in 88 other papers

The 3 markers were further tested as potential monitoring markers of response to defibrotide treatment and showed a trend toward normalization to non-SOS patient levels as early as 7 days after treatment.

also in 21,081 other papers